TrialJournal of Alzheimer's disease : JAD2017

Sembragiline in Moderate Alzheimer's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD).

Stephane Nave et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.